ICYMI: PURPOSE 2 Trial: Interim results show twice-yearly #lenacapavir injections reduce #HIV incidence by 96%, showing 99.9% efficacy. This long-acting #PrEP could revolutionize #HIV prevention, but questions around affordability &amp; access remain.
#lenacapavir
#lenacapavir #HIV #PrEP #HIV